Cargando…
Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152
Glioblastomas (GBMs) are the most aggressive primary brain tumors in adult and remain a therapeutic challenge. Targeting key apoptosis regulators with the ultimate aim to restore apoptosis in tumor cells could be an interesting therapeutic strategy. The inhibitors of apoptosis proteins (IAPs) are re...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108315/ https://www.ncbi.nlm.nih.gov/pubmed/27490930 http://dx.doi.org/10.1038/cddis.2016.214 |
_version_ | 1782467334795952128 |
---|---|
author | Tchoghandjian, A Soubéran, A Tabouret, E Colin, C Denicolaï, E Jiguet-Jiglaire, C El-Battari, A Villard, C Baeza-Kallee, N Figarella-Branger, D |
author_facet | Tchoghandjian, A Soubéran, A Tabouret, E Colin, C Denicolaï, E Jiguet-Jiglaire, C El-Battari, A Villard, C Baeza-Kallee, N Figarella-Branger, D |
author_sort | Tchoghandjian, A |
collection | PubMed |
description | Glioblastomas (GBMs) are the most aggressive primary brain tumors in adult and remain a therapeutic challenge. Targeting key apoptosis regulators with the ultimate aim to restore apoptosis in tumor cells could be an interesting therapeutic strategy. The inhibitors of apoptosis proteins (IAPs) are regulators of cell death and represent attractive targets, especially because they can be antagonized by SMAC mimetics. In this study, we first investigated the expression of cIAP1, cIAP2, XIAP and ML-IAP in human GBM samples and in four different cell lines. We showed that all GBM samples and GBM cell lines expressed all these IAPs, although the expression of each IAP varied from one case to another. We then showed that high level of ML-IAP predicted worse progression-free survival and overall survival in both univariate and multivariate analyses in two independent cohorts of 58 and 43 primary human GBMs. We then used GDC-0152, a SMAC mimetic that antagonizes these IAPs and confirmed that GDC-0152 treatment in vitro decreased IAPs in all the cell lines studied. It affected cell line viability and triggered apoptosis, although the effect was higher in U87MG and GL261 than in GBM6 and GBM9 cell lines. In vivo, GDC-0152 effect on U87MG orthotopic xenografts was dose dependent; it postponed tumor formation and slowed down tumor growth, significantly improving survival of GBM-bearing mice. This study revealed for the first time that ML-IAP protein expression correlates with GBM patient survival and that its antagonist GDC-0152 improves outcome in xenografted mouse. |
format | Online Article Text |
id | pubmed-5108315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51083152016-11-15 Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 Tchoghandjian, A Soubéran, A Tabouret, E Colin, C Denicolaï, E Jiguet-Jiglaire, C El-Battari, A Villard, C Baeza-Kallee, N Figarella-Branger, D Cell Death Dis Original Article Glioblastomas (GBMs) are the most aggressive primary brain tumors in adult and remain a therapeutic challenge. Targeting key apoptosis regulators with the ultimate aim to restore apoptosis in tumor cells could be an interesting therapeutic strategy. The inhibitors of apoptosis proteins (IAPs) are regulators of cell death and represent attractive targets, especially because they can be antagonized by SMAC mimetics. In this study, we first investigated the expression of cIAP1, cIAP2, XIAP and ML-IAP in human GBM samples and in four different cell lines. We showed that all GBM samples and GBM cell lines expressed all these IAPs, although the expression of each IAP varied from one case to another. We then showed that high level of ML-IAP predicted worse progression-free survival and overall survival in both univariate and multivariate analyses in two independent cohorts of 58 and 43 primary human GBMs. We then used GDC-0152, a SMAC mimetic that antagonizes these IAPs and confirmed that GDC-0152 treatment in vitro decreased IAPs in all the cell lines studied. It affected cell line viability and triggered apoptosis, although the effect was higher in U87MG and GL261 than in GBM6 and GBM9 cell lines. In vivo, GDC-0152 effect on U87MG orthotopic xenografts was dose dependent; it postponed tumor formation and slowed down tumor growth, significantly improving survival of GBM-bearing mice. This study revealed for the first time that ML-IAP protein expression correlates with GBM patient survival and that its antagonist GDC-0152 improves outcome in xenografted mouse. Nature Publishing Group 2016-08 2016-08-04 /pmc/articles/PMC5108315/ /pubmed/27490930 http://dx.doi.org/10.1038/cddis.2016.214 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Tchoghandjian, A Soubéran, A Tabouret, E Colin, C Denicolaï, E Jiguet-Jiglaire, C El-Battari, A Villard, C Baeza-Kallee, N Figarella-Branger, D Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 |
title | Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 |
title_full | Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 |
title_fullStr | Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 |
title_full_unstemmed | Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 |
title_short | Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 |
title_sort | inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by smac mimetic gdc-0152 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108315/ https://www.ncbi.nlm.nih.gov/pubmed/27490930 http://dx.doi.org/10.1038/cddis.2016.214 |
work_keys_str_mv | AT tchoghandjiana inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT souberana inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT tabourete inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT colinc inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT denicolaie inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT jiguetjiglairec inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT elbattaria inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT villardc inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT baezakalleen inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 AT figarellabrangerd inhibitorofapoptosisproteinexpressioninglioblastomasandtheirinvitroandinvivotargetingbysmacmimeticgdc0152 |